SYMTUZA® is the Only STR Studied in a Phase 3 Clinical Trial in a Rapid Initiation Scenario



SYMTUZA® is the First STR Proven in a Phase 3 Clinical Trial of Patients Rapidly Starting on Treatment1See 48-week results

Reference: 1.Huhn G, Crofoot G, Ramgopal M, et al. Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) rapid initiation for HIV-1 infection: primary analysis of the DIAMOND study. Poster presented at: 13th Annual American Conference for the Treatment of HIV (ACTHIV); April 11-13, 2019; Miami, Florida.


Model portrayals of patients.